Vericiguat Drug-drug Interaction With Nitroglycerin in Stable Coronary Artery Disease Patients
Completed
Merck Sharp & Dohme Corp.
Phase 1
2015-11-01
This study is intended to investigate the effect of nitroglycerin on vericiguat in patients
with stable coronary artery disease (CAD). Nitroglycerin is the standard therapy to treat
acute crisis of angina. Thus there is a high likelihood of co-administration of both drugs in
the target indication of vericiguat, worsening heart failure (HF). Therefore, it is important
to investigate the safety and tolerability of vericiguat and nitroglycerin, which may be used
as unprescribed on-demand treatment by patients with acute episodes of angina pectoris.
Vericiguat Drug-drug Interaction With Nitroglycerin in Stable Coronary Artery Disease Patients
Completed
Bayer
Phase 1
2015-11-01
This study is intended to investigate the effect of nitroglycerin on vericiguat in patients
with stable coronary artery disease (CAD). Nitroglycerin is the standard therapy to treat
acute crisis of angina. Thus there is a high likelihood of co-administration of both drugs in
the target indication of vericiguat, worsening heart failure (HF). Therefore, it is important
to investigate the safety and tolerability of vericiguat and nitroglycerin, which may be used
as unprescribed on-demand treatment by patients with acute episodes of angina pectoris.
A Study of Vericiguat in Participants With Heart Failure With Reduced Ejection Fraction (HFrEF) (MK-1242-001)
Completed
Bayer
Phase 3
2016-09-20
This is a randomized, placebo-controlled, parallel-group, multi-center, double-blind, event
driven study of vericiguat (MK-1242) in participants with heart failure with reduced ejection
fraction (HFrEF). The primary hypothesis is vericiguat (MK-1242) is superior to placebo in
increasing the time to first occurrence of the composite of cardiovascular (CV) death or
heart failure (HF) hospitalization in participants with HFrEF.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
